tiprankstipranks
Trending News
More News >
MicroPort Scientific Corp. (HK:0853)
:0853

MicroPort Scientific (0853) AI Stock Analysis

Compare
2 Followers

Top Page

HK

MicroPort Scientific

(OTC:0853)

Rating:44Neutral
Price Target:
MicroPort Scientific's overall stock score is heavily impacted by its weak financial performance, marked by persistent losses and high leverage. Technical analysis presents a mixed outlook with short-term consolidation but a negative momentum trend. Valuation concerns arise from a negative P/E ratio and lack of dividend yield, further impacting the stock's attractiveness.
Positive Factors
Balance Sheet Management
MicroPort Scientific Corp had a cash and financial asset balance of US$981 million against short-term bank borrowings, showing strong balance sheet management.
Export Sales
Total export sales are expected to increase by 80%+ YoY to US$170 million.
Sales Growth
MicroPort Scientific Corp guides 10-11% overall sales growth for 2025, with cardiovascular segment expecting growth at 15%+.
Negative Factors
Net Loss Forecast
The company has widened its net loss forecasts for the upcoming years due to harsh price cuts from bulk purchases.
Price Cuts
The scope of price cuts has expanded to include innovative devices and small sales volume products.
Research and Development
R&D expenses are expected to be cut significantly, delaying the progress of products in development and reducing future sales growth potential.

MicroPort Scientific (0853) vs. iShares MSCI Hong Kong ETF (EWH)

MicroPort Scientific Business Overview & Revenue Model

Company DescriptionMicroPort Scientific Corporation, an investment holding company, manufactures, and markets, and distributes medical devices in the People's Republic of China, North America, Europe, other Asian countries, South America, and internationally. The company's Cardiovascular Devices segment offers products and services for the treatment of coronary artery-related diseases; coronary stents and related delivery systems; and balloon catheters and accessories. Its Orthopedics Devices segment provides reconstructive joints, spine and trauma, and other professional implants and instruments. The company's Cardiac Rhythm Management Business segment offers defibrillators, cardiac resynchronization therapy devices, and pacemakers for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Its Endovascular and Peripheral Vascular Devices segment provides products and services for the interventional treatment of thoracic and abdominal aortic aneurysm, peripheral vascular diseases, aortic dissection, and other endovascular related diseases. The company's Neurovascular Devices segment offers neurovascular therapeutic and access devices for neurovascular diseases. Its Heart Valve Business segment provides VitaFlow Transcatheter aortic valve and delivery system, VitaFlow Liberty Transcatheter aortic valve implantation and retrievable delivery systems, Alwide Plus Balloon Catheter, various transcatheter aortic valve implantation, transcatheter mitral valve, transcatheter tricuspid valve, and surgical valve products. The company's Surgical Robot Business segment designs, develops, and commercializes surgical robots comprising robot ontology, control algorithm, electrical engineering, image-based navigation, and precision imaging. Its Surgical Devices segment researches and develops, manufactures, and sells surgical devices. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, the People's Republic of China.
How the Company Makes MoneyMicroPort Scientific makes money primarily through the sale of its medical devices and solutions across its various sectors. The company's revenue streams include the direct sale of products such as stents, pacemakers, orthopedic implants, and other specialized medical devices to healthcare providers and distributors worldwide. Additionally, MicroPort engages in strategic partnerships and collaborations to enhance its product offerings and market reach, thereby contributing to its revenue. The company's earnings are also influenced by its investment in research and development, which drives innovation and the introduction of new products to the market.

MicroPort Scientific Financial Statement Overview

Summary
MicroPort Scientific faces considerable financial challenges characterized by persistent losses, high leverage, and cash flow issues. Despite revenue growth, the company's profitability and liquidity remain weak, necessitating strategic improvements in cost management and operational efficiency to stabilize its financial position.
Income Statement
35
Negative
The income statement shows significant challenges in profitability, with a negative net income and EBIT over the past three years. Although there has been a revenue growth trend from 2020 to 2024, the company has consistently reported negative EBIT and net profit margins, indicating persistent operational inefficiencies and cost management issues.
Balance Sheet
40
Negative
The balance sheet highlights a concerning increase in total debt over the years, contributing to a high debt-to-equity ratio. Stockholders' equity has decreased significantly, reflecting financial instability. The equity ratio has also declined, indicating a heavier reliance on debt financing. These factors suggest potential solvency risks.
Cash Flow
30
Negative
The cash flow statement reveals negative operating cash flows, which paired with consistent negative free cash flows, indicates liquidity challenges. The company has been unable to generate positive cash flows from operations, relying heavily on financing activities to sustain operations, which poses a risk to financial health.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
1.03B950.73M840.83M778.64M648.73M
Gross Profit
574.09M532.10M501.77M491.77M436.03M
EBIT
-125.47M-516.17M-506.57M-339.24M-167.14M
EBITDA
-45.30M-382.54M-430.26M-251.29M-106.87M
Net Income Common Stockholders
-214.04M-477.63M-436.51M-351.30M-223.35M
Balance SheetCash, Cash Equivalents and Short-Term Investments
974.48M1.13B1.24B1.75B1.00B
Total Assets
3.63B3.93B3.99B4.38B2.47B
Total Debt
1.69B1.70B1.47B1.24B296.31M
Net Debt
972.21M679.20M264.94M-510.72M-705.77M
Total Liabilities
2.49B2.53B2.20B2.16B1.08B
Stockholders Equity
603.47M757.82M1.14B1.49B1.13B
Cash FlowFree Cash Flow
0.00-430.99M-600.58M-505.45M-143.58M
Operating Cash Flow
0.00-231.87M-343.30M-257.53M-23.20M
Investing Cash Flow
0.00-376.81M-412.75M-655.74M-148.13M
Financing Cash Flow
0.00434.90M273.00M1.66B846.89M

MicroPort Scientific Technical Analysis

Technical Analysis Sentiment
Positive
Last Price7.72
Price Trends
50DMA
7.20
Positive
100DMA
7.16
Positive
200DMA
6.59
Positive
Market Momentum
MACD
0.17
Negative
RSI
60.62
Neutral
STOCH
84.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0853, the sentiment is Positive. The current price of 7.72 is above the 20-day moving average (MA) of 7.05, above the 50-day MA of 7.20, and above the 200-day MA of 6.59, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 60.62 is Neutral, neither overbought nor oversold. The STOCH value of 84.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0853.

MicroPort Scientific Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
HK$6.72B22.5410.92%0.75%20.19%45.54%
78
Outperform
HK$7.21B25.9315.22%1.54%12.48%71.75%
65
Neutral
HK$6.35B31.144.39%4.37%-32.05%-54.47%
61
Neutral
HK$6.57B27.896.49%0.87%-18.05%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
44
Neutral
$14.28B-31.45%8.11%55.55%
44
Neutral
HK$16.44B-160.49%141.72%38.39%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0853
MicroPort Scientific
7.72
1.87
31.97%
HK:1302
LifeTech Scientific Corporation
1.52
-0.05
-3.18%
HK:1789
AK Medical Holdings Ltd.
6.00
0.98
19.52%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
11.18
2.33
26.33%
HK:2172
MicroPort NeuroTech Limited
12.34
4.45
56.40%
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
15.94
4.12
34.86%

MicroPort Scientific Corporate Events

MicroPort’s Endovastec Reports Q1 2025 Financial Results
Apr 29, 2025

Shanghai MicroPort Endovascular MedTech, a subsidiary of MicroPort Scientific, reported a decline in revenue and profit for the first quarter of 2025 compared to the same period in 2024. Despite the decrease in financial performance, the company’s total assets and equity showed slight growth, indicating a stable financial position amid challenging market conditions.

MicroPort Scientific Announces 2025 Annual General Meeting and Key Resolutions
Apr 29, 2025

MicroPort Scientific Corporation has announced its Annual General Meeting scheduled for May 30, 2025, in Shanghai, China. Key resolutions include the re-election of directors, approval of financial statements, and granting mandates for share buybacks and issuance. These actions are significant for maintaining the company’s governance and operational flexibility, potentially impacting its market positioning and shareholder value.

MicroPort Scientific Grants Share Options to Employees
Apr 1, 2025

MicroPort Scientific Corporation has announced the grant of 3,408,502 share options to 24 eligible employees under its Share Scheme, which was adopted on 19 June 2023. The options, valid for ten years starting from 1 April 2025, are intended to incentivize employees based on their performance and contributions, without additional performance targets. The exercise price is set at HK$8.34 per share, aligning with the average closing price of the shares prior to the grant date. This move aims to promote the development and success of the company’s business, with a clawback mechanism in place to ensure alignment with the company’s objectives.

MicroPort Scientific Reports Improved Financial Results and Global Expansion
Mar 28, 2025

MicroPort Scientific announced its annual results for the year ended December 31, 2024, reporting a revenue increase of 10% year-on-year, excluding foreign exchange impacts, and a significant narrowing of net loss by 59%. The company attributed this improvement to increased international sales, strategic divestments, and enhanced operational efficiency. MicroPort’s global commercialization platform has enabled its products to reach over 20,000 hospitals in more than 100 countries, strengthening its market position and expanding its competitive edge. The company remains focused on financial health and core business operations to drive sustainable growth.

MicroPort Scientific Schedules Board Meeting to Review 2024 Financial Results
Mar 18, 2025

MicroPort Scientific Corporation has announced a board meeting scheduled for March 28, 2025, to consider and approve the company’s final results for the year ending December 31, 2024. This meeting is significant as it will address the company’s financial performance and potentially impact its strategic decisions and stakeholder interests.

MicroPort’s Endovastec Reports Revenue and Profit Growth Amid Equity Decline
Feb 27, 2025

Shanghai MicroPort Endovascular MedTech (Endovastec), a subsidiary of MicroPort Scientific Corporation, reported a 1.6% increase in revenue and a 13.4% rise in profit for the year ending December 31, 2024. Despite these gains, the total equity attributable to equity owners saw a slight decrease of 1.4%. The financial results, prepared under PRC accounting standards, are unaudited and only reflect Endovastec’s operations, not the entire group, prompting caution among investors.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.